Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-HASTE: Rapid Start Bictegravir in HIV
NCT04249037Phase 4Terminated
- Sponsor
- University of Colorado Denver
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Viral Suppression at 48 weeks. Started Dec 2020; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04249037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249037.